
Opinion|Videos|October 7, 2024
Emerging Treatments for Atopic Dermatitis
Key Takeaways
- Emerging therapies, including biologics and small molecules, are promising for moderate to severe atopic dermatitis management.
- Clinicians should adopt a personalized approach, considering patient-specific factors and maintaining open communication.
Looking to the future of atopic dermatitis treatment, the panel discusses ongoing research and promising emerging therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Are there any ongoing atopic dermatitis studies or emerging therapies that you are excited about?
- What advice would you like to share with clinicians taking care of patients with moderate/severe atopic dermatitis?
Advertisement
Related to this article

April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on HCPLive
1
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
2
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
3
5 Gastroenterology Headlines You Missed in September 2026
4
6 Nephrology Headlines You Missed in September 2026
5

